Cancer chemoprevention through interruption of multistage carcinogenesisthe lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer

European Journal of Cancer

Volumn 36, Issue 3, 2000, Pages 314-329

  Marks, F ^a   Furstenberger G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

APC gene; Arachidonic acid metabolism; Cyclooxygenase 2; Genetic instability; Lipoxygenases; Non steroidal anti inflammatory drugs; Prostaglandins; Signal transduction; Tumour promotion

Indexed keywords

CYCLOOXYGENASE 2; FREE RADICAL; MALONALDEHYDE; NONSTEROID ANTIINFLAMMATORY AGENT; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ARACHIDONIC ACID METABOLISM; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CANCER; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; IMMUNE DEFICIENCY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TISSUE REPAIR; TUMOR GROWTH;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DINOPROST; DOWN-REGULATION; EICOSANOIDS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 0033996080     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00318-4     Document Type: Review

References (165)

1. Ito N, Hasegawa R, Imaida K, Hirose M, Asamoto M, Shirai T. Concepts in multistage carcinogenesis. Crit Rev Oncol Hematol 1995, 21, 105-133.
2. Loeb LA. Cancer cells exhibit a imitator phenotype. Adv Cancer Res 1998, 72, 26-56.
3. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA 1995, 92, 5258-5265.
4. Sies H. Oxidative stress and antioxidants. London, Academic Press, 1991.
5. Tanaka T. Effect of diet on human carcinogenesis. Crit Rev Oncol Hematol 1997, 25, 73-95.
6. Lupulescu A. The role of hormones, growth factors, and vitamins in carcinogenesis. Crit Rev Oncol Hematol 1996, 23, 95-130.
7. Shaw IC, Jones HB. Mechanisms of non-genotoxic carcinogenesis. Trends in Pharmacol Sci 1994, 15, 89-93.
8. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992, 54, 63-128.
9. Marks F, Fürstenberger G. Tumor promotion in skin. In Arcos JC, ed. Chemical Induction of Cancer. Boston, Birkhäuser, 1995, 125-160.
10. Fürstenberger G, Rogers M, Schnapke R, Bauer G, Höfler P, Marks F. Stimulatory role of transforming growth factors in multistage skin carcinogenesis: possible explanation for the tumor inducing effect of wounding in initiated NMRI mouse skin. Int J Cancer 1989, 43, 915-921.
11. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nature Med 1999, 5, 823-831.
12. Grasso P, Sharratt M, Cohen AJ. Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu Rev Pharmacol Toxicol 1991, 31, 253-287.
13. Orth J. Präcarcinomatöse Krankheiten und künstliche Krebse. Z Krebsforsch 1911, 10, 42-50.
14. Brown K, Kemp C, Burns P, Balmain A. Importance of genetic alterations in tumour development. Arch Toxicol 1994, 16(Suppl.), 253-260.
15. Fürstenberger G, Kopp-Schneider A. Malignant progression of papillomas induced by the initiation-promotion protocol in NMRI mouse skin. Carcinogenesis 1995, 16, 61-69.
16. Portella G, Liddell J, Crombie R, et al. Molecular mechanisms of invasion and metastasis during mouse skin tumor progression. Invasion Metast 1994, 14, 1-6.
17. Linardopoulos S, Street AJ, Quelle DE, et al. Deletion and altered regulation of p16 (INK4a) and p15 (INK4b) in undifferentiated mouse skin tumors. Cancer Res 1995, 55, 5168-5172.
18. Kinzler KW, Vogelstein B. Lessons learned from hereditary colon cancer. Cell 1996, 87, 159-170.
19. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997, 278, 1043-1050.
20. Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1997, 1332, F25-F48.
21. Reddy BS. Tumor promotion in colon carcinogenesis. In Slaga TJ, ed. Mechanisms of tumor promotion, vol. 1. Boca Raton, CRC Press, 1983, 108-128.
22. Nagengast FM, Grubben MJAL, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995, 31A, 1067-1070.
23. Craven PA, Pfanstiel J, DeRobertis FR. Role of activation of protein kinase C in the stimulation of colonic epithelial proliferation and reactive oxygen formation by bile acids. J Clin Invest 1987, 79, 532-541.
24. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998, 273, 2424-2436.
25. Potter JD. Risk factors for colon neoplasia - epidemiology and biology. Eur J Cancer 1995, 31A, 1033-1038.
26. Giovannucci E, Willett WC. Dietary factors and risk of colon cancer. Ann Med 1994, 26, 443-452.
27. Moore MA, Park CB, Tsuda H. Soluble and insoluble fiber influences on cancer development. Crit Rev Oncol Hematol 1998, 27, 229-242.
28. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992, 52, 5575-5589.
29. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983, 24, 83-87.
30. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997, 39, 1-20.
31. Schreinemachers DM, Everson RB. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology 1994, 5, 138-146.
32. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and the risk of fatal cancer. Cancer Res 1993, 53, 1322-1327.
33. Gupta RA, DuBois RN. Aspirin, NSAIDs, and colon cancer prevention: mechanisms? Gastroenterology 1998, 114, 1095-1100.
34. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive action. Gastroenterology 1998, 113, 1992-1998.
35. Elder DJE, Paraskeva C. NSAIDs to prevent colorectal cancer: a question of sensitivity. Gastroenterology 1997, 113, 1999-2008.
36. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metast Rev 1994, 13, 241-256.
37. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996, 270, 6393-6400.
38. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 1989, 86, 1178-1182.
39. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266, 12866-12872.
40. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996, 56, 4566-4569.
41. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998, 58, 409-412.
42. Nakatsugi S, Fukutake M, Takahashi M, et al. Suppression of intestinal polyp development by Nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Japan J Cancer Res 1997,88, 1117-1120.
43. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996, 87, 803-809.
44. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995, 83, 493-501.
45. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997, 99, 2250-2259.
46. Sheng HM, Shao JY, Morrow JD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58, 362-366.
47. Hao X, Bishop AE, Wallace M, et al. Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999, 187, 295-301.
48. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997, 57, 1270-1280.
49. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implication for the development of skin cancer. Carcinogenesis 1998, 19, 723-729.
50. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and the neck. Cancer Res 1999, 59, 991-994.
51. Müller-Decker K, Reinerth G, Krieg P, et al. Expression of prostaglandin-H synthase isozymes in normal human skin and epidermal neoplasias. Int J Cancer 1999, 80, 648-656.
52. Wolff H, Saukonen K, Anttila S, Korjalainen A, Vaino H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998, 58, 4997-5001.
53. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999, 11, 412-418.
54. Ratnasinghe D, Tangrea J, Roth MJ, et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus: an immunohistochemical study. Anticancer Res 1999, 19, 171-174.
55. Zimmermann KC, Sarbi M, Wber AA, Borchard F, Gabbert HE, Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59, 198-204.
56. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepato-cellular carcinoma. Hepato-Gastroenterol 1999, 46, 407-412.
57. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999, 29, 688-696.
58. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenäse expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59, 987-990.
59. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90, 455-460.
60. Hendel J, Nielson OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 1997, 92, 297-306.
61. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase-2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1999, 115, 297-306.
62. Müller-Decker K, Albert C, Lukanov T, Winde GMarks F, Füstenberger G. Cellular localization of cyclooxygenase isozymes in Crohn's disease and colorectal cancer. Int J Colorectal Dis 1999, 14, 212-218.
63. Sawaoka H, Kawano S, Tsujii S, et al. Heliobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostagl Leukotr Essent Fatty Acids 1998, 59, 313-316.
64. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998, 95, 681-686.
65. Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG. Sodium salicylate inhibits cyclooxygenase-2 activity independently of transcription factor (nuclear factor kappa B) activation: role of arachidonic acid. Molec Pharmacol 1997, 51, 907-912.
66. Kipp E, Gosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265, 956-959.
67. Yin MY, Yamamoto Y, Gaynor RB. The antiinflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature 1998, 396, 77-80.
68. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor κB and nuclear factor interleukin-6 in tumor necrosis factor-α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995, 270, 31315-31320.
69. Jobin C, Morteau O, Han DS, Sartor RB. Specific NF-κB blockade selectively inhibits tumor necrosis factor-α-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998, 95, 537-543.
70. Huang C, Ma WY, Hahnenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997, 272, 26325-26331.
71. Xie W, Herschman HR. Transcriptional regulation of prostaglandin-2 gene expression by platelet-derived growth factor and serum. J Biol Chem 1996, 271, 31742-31748.
72. Lehman JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1997, 272, 3406-3410.
73. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999, 274, 8328-8334.
74. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators. Nature 1998, 393, 790-793.
75. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 1998, 18, 78-84.
76. Schwenger P, Bellosta P, Victor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate inhibits apoptosis via p38 mitogen-activated protein kinase but inhibits TNFα-induced cJun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997, 94, 2869-2873.
77. Fürstenberger G, Gross M, Marks F. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 1989, 10, 91-96.
78. Marks F. Hyperplastic transformation: the response of the skin to irritation. In Galli CL, Hensby CN, Marinovich M, eds. Skin pharmacology and toxicology. New York and London, Plenum Press, 1990, 121-146.
79. Müller-Decker K, Scholz K, Marks F, Fürstenberger G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Molec Carcinogenesis 1995, 12, 31-41.
80. Müller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Fürstenberger G. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin-tumor promotion by PGHS-2 inhibition. Molec Carcinogenesis 1998, 23, 36-44.
81. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Molec Carcinogenesis 1999, 25, 231-240.
82. Pentland AP, Schoggins JW, Scott GA, Khan KNM, Han RJ. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999, 20, 1939-1944.
83. Tiano H, Chulada P, Spalding J, et al. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Proc Am Assoc Cancer Res 1997, 38, 257.
84. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55, 3785-3789.
85. Harris JE, Braun DP, Anderson KM, eds. Prostaglandin Inhibitors in tumor immunology and immunotherapy. Boca Raton, CRC Press, 1994.
86. Smith BJ, Curtis JF, Eling TE. Bioactivation of xenobiotics by prostaglandin H synthase. Chem Biol Interact 1991, 79, 245-264.
87. Ushikubi F, Hirata M, Narumiya S. Molecular biology of prostanoid receptors: an overview. J Lipid Med Cell Signall 1995, 12, 343-359.
88. Bhattacharya M, Peri KG, Almazan G, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 1998, 22, 15792-15797.
89. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74, 49-139.
90. 2 in human colon cancer cells. Cancer Res 1998, 58, 362-366.
91. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52, 237-245.
92. Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997, 57, 2452-2459.
93. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997, 94, 4318-4323.
94. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 1998, 19, 49-53.
95. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Molec Cell 1999, 9, 799-809.
96. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med 1998, 4, 1053-1057.
97. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR enhance colon polyp formation? Nature Med 1998, 4, 1058-1061.
98. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med 1998, 4, 1046-1052.
99. Gilroy DW, Colville-Nash PR, Willis D, et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med 1999, 5, 698-701.
100. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94, 3336-3340.
101. Tsuji M, Kawano S, Tsuji H, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
102. Hull MA, Thompson JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999, 45, 529-536.
103. 1 and copper in angiogenesis. J Natl Cancer Inst 1982, 69, 475-482.
104. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372, 83-87.
105. Seed MP, Brown JR, Freemantle CN, et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topically diclofenac in 2.5% hyluronan. Cancer Res 1997, 57, 1625-1629.
106. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as play makers of tumorigenesis. Int J Molec Med 1998, 2, 715-719.
107. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997, 11, 234-247.
108. Marnett LJ. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 1995, 13, 303-308.
109. Krieg P, Kinzig A, Ress-Löschke M, et al. 12-Lipoxygenase isoenzymes in mouse skin tumor development. Molec Carcinogenesis 1995, 14, 118-129.
110. Bürger F, Krieg P, Kinzig A, Schurich B, Marks F, Fürstenberger G. Constitutive expression of 8-lipoxygenase in papillomas and clastogenic effect of lipoxygenase-derived arachidonic acid metabolites in keratinocytes. Molec Carcinogenesis 1999, 24, 108-118.
111. Petrusevska RT, Fürstenberger G, Marks F, Fusenig NE. Cytogenetic effects caused by phorbol ester tumor promoters in primary mouse keratinocyte cultures: correlation with convertogenic activity of TPA in multistage carcinogenesis. Carcinogenesis 1988, 9, 1207-1215.
112. Ara G, Teicher BA. Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids 1996, 54, 3-16.
113. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999, 155, 235-245.
114. Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999, 59, 360-366.
115. Honn KV, Tang DG, Gao X, et al. 12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metast Rev 1994, 13, 365-396.
116. 2). FEBS Lett 1997, 410, 49-53.
117. Vadas P, Browning J, Edelson J, Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationships with associated disease states. J Lipid Med 1993, 8, 1-30.
118. 2. Biochim Biophys Acta 1993, 170, 217-231.
119. 2 is phosphorylated and activated by MAPkinase. Cell 1993, 72, 269-278.
120. Cai H, Smola U, Wixler V, et al. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein. J Mol Cell Biol 1997, 17, 732-741.
121. 2. Adv Exp Med Biol 1997, 407, 163-170.
122. 2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem 1998, 273, 1733-1752.
123. Murakami M, Kuwata H, Amakasu Y, Shimbra S, et al. Prostaglandin E2 amplifies cytosolic phospholipase A2- and cylcooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. J Biol Chem 1997, 272, 19891-19905.
124. 2 in rats. Toxicology 1998, 126, 65-73.
125. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem 1997, 272, 14501-14505.
126. 2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 1998, 58, 500-503.
127. 1 and TGFα in primary keratinocytes and papillomas expressing v-Ha-ras. Molec Carcinogenesis 1991, 4, 210-219.
128. Imamoto A, Beltran LM, DiGiovanni J. Evidence for autocrine/paracrine growth stimulation by TGFα during the process of skin tumor promotion. Molec Carcinogenesis 1991, 4, 52-60.
129. Coffey RJ, Graves-Deal R, Dempsey PJ, Whitehead RH, Pittelkow MR. Differential regulation of TGFα autoinduction in a nontransformed and transformed epithelial cell. Cell Growth Different 1992, 3, 347-354.
130. Klein SB, Fisher GJ, Jensen TC, Mendelsohn J, Voorhees JJ, Elder JT. Regulation of TGFα expression in human keratinocytes: PKC-dependent and -independent pathways. J Cell Physiol 1992, 151, 326-336.
131. DuBois RN, Awad J, Morrow J, Roberts II LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by TGFα and phorbol ester. J Clin Invest 1994, 93, 493-498.
132. Matsura H, Sakaue M, Subbamaraiah K, et al. Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem 1999, 41, 29138-29148.
133. Yuspa SH, Dlugosz AA, Denning MF, Glick AB. Multistage carcinogenesis in the skin. J Invest Dermatol Symp Proc 1996, 1, 147-150.
134. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-2 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998, 273, 22120-22127.
135. Dominey AM, Wang XJ, King Jr LE, et al. Targeted overexpression of TGFα in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous squamous papillomas. Cell Growth Different 1993, 4, 1071-1088.
136. Vassar R, Hutton ME, Fuchs E. Transgenic overexpression of TGFα bypasses the need for cHa-ras mutations in mouse skin tumorigenesis. Molec Cell Biol 1992, 12, 4643-4653.
137. 2. J Biol Chem 1996, 271, 27723-27729.
138. Hernandez M, Bayon Y, Sanchez-Crespo M, Nieto ML. Thrombin produces phosphorylation of cytosolic cPLA2 by a mitogen-activated protein kinase-independent mechanism in the human astrocytoma cell line 1321N1. Biochem J 1997, 328, 263-269.
139. Xie W, Herschman HR. Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growth factor and serum. J Biol Chem 1996, 271, 31742-31748.
140. Guan Z, Buckman SY, Pentland AP, Templeton DJ, Morrison AR. Induction of cyclooxygenase-2 by the activated MEKK1-SEK1/MKK4-p38 mitogen-activated protein kinase pathway. J Biol Chem 1998, 273, 12901-12908.
141. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997, 1333, F86-F104.
142. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997, 1332, F127-F147.
143. Willert K, Nusse R. β-catenin: a key mediator of Wnt signaling. Curr Opin Genetics Develop 1998, 8, 85-102.
144. Nusse R, Varmus HE. Wnt genes. Cell 1992, 69, 1073-1087.
145. Gumbiner BM. A balance between β-catenin and APC. Current Biol 1997, 7, R443-R446.
146. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996, 61, 514-523.
147. Barth IM, Näthke IS, Nelson WJ. Cadherins, catenins, and APC protein: interplay between cycloskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997, 9, 683-690.
148. Korinek V, Barker N, Morin PH, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275, 1784-1787.
149. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997, 275, 1787-1790.
150. Rubinfeld B, Robbins P, El-Gamil M, et al. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997, 275, 1790-1792.
151. Peltomäki P, dela Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 1997, 70, 93-119.
152. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown MC. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res 1999, 59, 1572-1577.
153. Kutchera W, Jonas DA, Matsonami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer. Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996, 93, 4816-4820.
154. Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 1996, 87, 783-786.
155. Bullions LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 1998, 10, 81-87.
156. Näthke IS, Adams P, Polakis JH, Sellin WJ, Nelson C. The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration. J Cell Biol 1996, 134, 165-179.
157. Normanno N, de Luca A, Salomon DS, Ciardiello F. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. Cancer Detect Prevent 1998, 22, 62-67.
158. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997, 94, 657-662.
159. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelson J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18, 305-314.
160. Rajagopal S, Huang S, Moskal TL, Lee B, EI-Naggar AK, Chakrabarty S. Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. Int J Cancer 1995, 62, 661-667.
161. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999, 274, 10911-10915.
162. Marks F. Multistage skin carcinogenesis in mice as a model of colorectal carcinogenesis in humans. In Schmiegel W, Schölmerich J, eds. Colorectal cancer. Dordrecht, Kluwer, 1999, 48-66.
163. Marks F, Fürstenberger G, Müller-Decker K. Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. In Senn H-J, Costa A, Jordan VC, eds. Chemoprevention of Cancer. Berlin, Springer, 1999, 45-70.
164. Marks F. Arachidonic acid and companions: an abundant source of biological signals. In Marks F, Fürstenberger G, eds. Prostaglandins, leukotrienes and other eicosanoids: from biogenesis to clinical application. Wiley-VCH, Weinheim, 1999, 1-46.
165. Marks F, Fürstenberger G. Eicosanoids and cancer. In Marks F, Fürstenberger G, eds. Prostaglandins, leukotrienes and other eicosanoids: from biogenesis to clinical application. Weinheim, Wiley-VCH, 1999, 303-330.